Radioactive drug aims to shrink Hard-to-Treat gut tumors
NCT ID NCT04919226
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests a radioactive drug called 177Lu-Edotreotide against standard chemotherapy for people with aggressive neuroendocrine tumors of the gut or pancreas. The drug targets tumor cells and delivers radiation directly. About 259 participants will be followed to see if the treatment slows tumor growth and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-Edotreotide (a radioactive drug that targets tumor cells)
What this could lead to
If successful, this treatment could slow tumor growth and extend survival for people with aggressive neuroendocrine tumors that are hard to treat.
What could go wrong
This is a Phase 3 trial, but results are not yet final. The treatment involves radiation, which can cause side effects like kidney damage or low blood counts. It may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Jiangnan University
Wuxi, 214122, China
-
All India Institute Of Medical Sciences, Nuclear Medicine
New Delhi, National Capital Territory of Delhi, 110029, India
-
Central University Hospital de Asturias (HUCA), IUOPA - Universitary Institute of Oncology
Oviedo, 33011, Spain
-
Charite - University Hospital Berlin
Berlin, 13353, Germany
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University School of Medicine, Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Edouard Herriot Hospital, Medical Oncology Unit
Lyon, 69003, France
-
Erasmus University Medical Center Rotterdam
Rotterdam, 3015 GD, Netherlands
-
European Institute of Oncology (IEO), IRCCS
Milan, 20141, Italy
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111-2497, United States
-
Fudan University Shanghai Cancer Center
Shanghai, 200000, China
-
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
-
HCG Cancer Centre, Medical Oncology
Bangalore, Karnataka, 560027, India
-
Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology
Pessac, Bordeaux, 33604, France
-
ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute
New York, New York, 10128, United States
-
ICO Hospitalet, Catalan Institute of Oncology
Barcelona, 199-203, Spain
-
IUCT Oncopole - Institut Universitaire du Cancer de Toulouse
Toulouse, 31059, France
-
King's College Hospital
London, SE5 9RS, United Kingdom
-
Mayo Clinic - Rochester, Department of Oncology
Rochester, Minnesota, 55905, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Nantes University Hospital Center - Hotel Dieu Hospital
Nantes, Cedex, 44093, France
-
Oregon Health and Science University
Portland, Oregon, 97239-3098, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, VIC 3000, Australia
-
Royal North Shore Hospital
St Leonards, New South Wales, 2065, Australia
-
Stanford Cancer Center
Palo Alto, California, 94305, United States
-
Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging
Mumbai, 400012, India
-
Texas Oncology
Dallas, Texas, 75246, United States
-
University Duisburg-Essen, University Hospital Essen, Clinic for Nuclear Medicine
Essen, 45147, Germany
-
University General Hospital Gregorio Maranon
Madrid, 28007, Spain
-
University Hospital 12 de Octubre, Department of Gastroenterology
Madrid, 28041, Spain
-
University Hospital Bonn, Department of Nuclear Medicine
Bonn, 53127, Germany
-
University Hospital Complex of Santiago (CHUS)
Santiago de Compostela, 15706, Spain
-
University Hospital Erlangen, Department of Internal Medicine I - Endocrinology
Erlangen, 91054, Germany
-
University Hospital Vall d'Hebron, Department of Medical Oncology
Barcelona, 08035, Spain
-
University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Complex Operative Unit of Medical Oncology
Rome, 00168, Italy
-
University Polyclinic Hospital "G. Martino", Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging, Complex Operational Unit of Nuclear Medicine
Messina, 98125, Italy
-
University and Polytechnic Hospital La Fe, Endocrinology
Valencia, 46026, Spain
-
University of Colorado Hospital, Nuclear Medicine
Aurora, Colorado, 80045, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
VU Medical Center (VUMC), Department of Medical Oncology
Amsterdam, 1081-HV, Netherlands
-
Washington University Alvin J. Siteman Cancer Center
St Louis, Missouri, 63110, United States